FIG 4.

Changes in HCV RNA levels from baseline in patients with baseline NS5A RAVs who received ABT-530. Data are presented as the changes in HCV RNA levels from baseline 0 to 72 h after the first dose for each patient with baseline NS5A RAVs, compared to the mean decline curves for all patients in the corresponding ABT-530 dose groups. (A) 15 mg. (B) 40 mg. (C) 120 mg. (D) 400 mg. (E) 120 mg (with cirrhosis). Standard deviations within each dose group are shown as error bars. RAVs are listed in parentheses, and a mixture of amino acids detected at a position is denoted by a slash.